---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007238"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:53:13.345280+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# CNS Pharmaceuticals posts investor video on Berubicin trial

## Summary
- CEO John Climaco discusses Berubicin clinical trial in Virtual Investor event.
- Event link posted on October 18, 2023; no financial data or trial results disclosed in 8-K.
- No specific quantitative updates or forward guidance provided in the filing.

## SEC filing metadata
- accession: 0001683168-23-007238
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823007238/0001683168-23-007238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823007238/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007238
- JSON: https://secwatch.observer/filing/0001683168-23-007238.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.